Background

Mutations occurring in the tumor suppressor gene TP53 are more prevalent in cases of tumor recurrence, often leading to an aggressive and refractory disease with a poor therapeutic response in patients. Current genomic editing technologies are thus focused on replacing mutated gene sequences with correct ones. The CRISPR system (Clustered Regularly Interspaced Short Palindromic Repeats) represents one of these genetic editing strategies, wherein a molecule of RNA, known as guide RNA (gRNA), directs an endonuclease enzyme, in this case the Cpf1 enzyme, to a specific target site on the genome, resulting in a precise double-stranded DNA cut.

Despite numerous clinical studies employing CRISPR-Cas systems, the accuracy of their mechanisms of action remains a crucial point limiting the widespread adoption